Last Update: Apr 20, 2026 A Post Approval Surveillance of Scemblix® (Asciminib) in Patients With Chronic Myeloid Leukemia (CML) in Korea ClinicalTrials.gov Identifier: [NCT05943522](https://clinicaltrials.gov/ct2/show/NCT05943522) Novartis Reference Number:CABL001A2006 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients. The dosage and duration of treatment may be considered and decided by the investigator in accordance with prescribing information of Asciminib. This study will enroll all patients by total enumeration for those prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice for 2 years after the market launch. Condition Chronic Myeloid Leukemia Overall Status Recruiting Number of Participants600 Start Date Jul 19, 2023 Completion Date Jun 07, 2030 Gender All Age(s) 18 Years - 100 Years (Adult, Older Adult) ## Interventions Other ### Asciminib There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis ## Eligibility Criteria Inclusion criteria 1\. Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label 2\. Patients who are willing to provide written informed consent prior to study enrollment Exclusion criteria 1\. Patients with contraindication according to locally approved label of Scemblix® 2\. Patients who receive or are going to receive any investigational medicine during the observation period South Korea #### Novartis Investigative Site Recruiting Anyang-si,Gyeonggi-do,14068,South Korea #### Novartis Investigative Site Recruiting Seoul,06591,South Korea #### Novartis Investigative Site Recruiting Suwon,Yeongtong Gu,16499,South Korea #### Novartis Investigative Site Recruiting Seoul,Yangcheon gu,07985,South Korea #### Novartis Investigative Site Recruiting Seoul,Seoul,06351,South Korea #### Novartis Investigative Site Recruiting Seoul,Seoul,03080,South Korea #### Novartis Investigative Site Recruiting Seoul,Korea,02841,South Korea #### Novartis Investigative Site Recruiting Incheon,Korea,405 760,South Korea #### Novartis Investigative Site Recruiting Bucheon-si,Gyeonggi-do,14584,South Korea #### Novartis Investigative Site Recruiting Wŏnju,Gangwon-do,26426,South Korea #### Novartis Investigative Site Recruiting Taegu,41944,South Korea #### Novartis Investigative Site Recruiting Seoul,05505,South Korea #### Novartis Investigative Site Recruiting Seoul,03722,South Korea #### Novartis Investigative Site Recruiting Pusan,614 735,South Korea #### Novartis Investigative Site Recruiting Jeollanam,519763,South Korea #### Novartis Investigative Site Recruiting Gyeonggi-do,Korea,10408,South Korea #### Novartis Investigative Site Recruiting Uijeongbu-si,Gyeonggi-do,11759,South Korea ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: